Taken together, we can conclude that 1A-116 is a PPI inhibitor able to selectively bind to W56 residue in Rac1 protein structure and may represent a suitable therapeutic agent for different types of neoplasms as well as pre-malignant disorders involving hyperproliferative phenotypes. This evidence concerns the gene RAC1 and neoplasm.